People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Beam Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $218.6M | $4.8B | 2018 |
| Verve Therapeutics, Inc. | — | Biotechnology | Series C | $94.0M | $3.1B | 2021 |
| Vitro Biopharma, Inc. | — | Biotechnology | Seed | $7.1M | $293K | 2020 |
| Accufix Holdings, Inc. | — | Biotechnology | Seed | $4.2M | $46.7M | 2020 |
John Evans at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Evans on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Robert Nelson | 1 | 7 |
| STEPHEN KNIGHT | 1 | 6 |
| Krishna Yeshwant | 1 | 5 |
| JOHN BROWN | 1 | 4 |
| Michael Yi | 1 | 4 |
| Mark Fishman | 1 | 3 |
| Feng Zhang | 1 | 3 |
| Jack Zamora | 1 | 2 |
| Andrew Bellinger | 1 | 2 |
| Caroline R Mosessian | 1 | 1 |
| James Lineberger | 1 | 1 |
| Robert Torney | 1 | 1 |
| Glenn Vitale | 1 | 1 |
| Michael Parisi | 1 | 1 |
| William Greim | 1 | 1 |
| Keith A Hamilton | 1 | 1 |
| James E. Lineberger | 1 | 1 |
| Andrew Ashe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.